6:45 PM
May 05, 2016
 |  BC Extra  |  Company News

Wave, Pfizer begin metabolic disease collaboration

Wave Life Sciences Ltd. (NASDAQ:WVE) and Pfizer Inc. (NYSE:PFE) partnered to design and develop stereopure nucleic acid therapeutics for metabolic diseases. The partners will investigate therapies for five genetically defined hepatic targets selected by the pharma.

Wave will design and develop the nucleic acids from discovery through clinical candidate selection. The biotech will use Pfizer's hepatic targeting technology and its...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >